Subscribe to NRx Newsletter


Aviptadil Right to Try – for US-licensed physicians who wish to obtain Aviptadil under Right to Try law for Critical COVID-19 patients with no therapeutic alternative

At NRx Pharmaceuticals, we are committed to including patients in need of potentially lifesaving cures in our development programs at the earliest opportunity. During the initial stages of development, this may take the form of “named patient” Investigational New Drug licensing that must be approved by the US Food and Drug Administration (FDA) on an individual basis. As development continues, we may initiate Expanded Access programs (previously known as compassionate care) with the encouragement of the FDA.